DUBLIN – Shares in Verona Pharma plc rose as much as 21 percent Friday as the company reported that a single dose of its dual phosphodiesterase (PDE) 3 and 4 inhibitor, RPL-554, improved lung function in cystic fibrosis (CF) patients.